UNIVERSAL is a European-African Project that will develop treatments for children living with HIV.
The project will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing first-line therapy who need to switch to a new treatment regimen.
These two new formulations contain approved drugs already used in adult care in high-income settings: dolutegravir combined with emtricitabine/tenofovir alafenamide; and darunavir/ritonavir.
The project involves 15 partners from Cameroon, Spain, Netherlands, Uganda, France, Mali, United Kingdom, Senegal, Ivory Coast, Switzerland, United States and Zimbabwe.
UNIVERSAL Press Release
03/02/2021 – New European-African collaboration to develop UNIVERSAL treatments for children living with HIV